Two Sigma Advisers’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-20,655
| Closed | -$1.66M | – | 2414 |
|
|
2024
Q3 | $1.66M | Sell |
20,655
-26,100
| -56% | -$2.11M | ﹤0.01% | 1168 |
|
|
2024
Q2 | $3.87M | Sell |
46,755
-15,800
| -25% | -$1.39M | 0.01% | 880 |
|
|
2024
Q1 | $5.34M | Sell |
62,555
-67,800
| -52% | -$5.32M | 0.01% | 755 |
|
|
2023
Q4 | $11.1M | Sell |
130,355
-90,400
| -41% | -$7.82M | 0.03% | 488 |
|
|
2023
Q3 | $19.8M | Sell |
220,755
-29,800
| -12% | -$2.66M | 0.05% | 316 |
|
|
2023
Q2 | $21.3M | Sell |
250,555
-31,400
| -11% | -$2.65M | 0.05% | 297 |
|
|
2023
Q1 | $23.3M | Sell |
281,955
-24,500
| -8% | -$1.98M | 0.06% | 290 |
|
|
2022
Q4 | $24.1M | Sell |
306,455
-40,000
| -12% | -$3.22M | 0.07% | 291 |
|
|
2022
Q3 | $25.6M | Sell |
346,455
-64,900
| -16% | -$4.66M | 0.07% | 263 |
|
|
2022
Q2 | $26.8M | Sell |
411,355
-4,200
| -1% | -$249K | 0.08% | 266 |
|
|
2022
Q1 | $26.3M | Buy |
415,555
+115,100
| +38% | +$6.26M | 0.07% | 265 |
|
|
2021
Q4 | $15.9M | Buy |
300,455
+3,900
| +1% | +$238K | 0.04% | 365 |
|
|
2021
Q3 | $20.9M | Buy |
296,555
+192,600
| +185% | +$12.2M | 0.05% | 307 |
|
|
2021
Q2 | $6.93M | Sell |
103,955
-64,500
| -38% | -$4.56M | 0.02% | 710 |
|
|
2021
Q1 | $18.7M | Sell |
168,455
-101,300
| -38% | -$12.5M | 0.05% | 379 |
|
|
2020
Q4 | $32M | Sell |
269,755
-236,700
| -47% | -$25.5M | 0.09% | 244 |
|
|
2020
Q3 | $44.2M | Buy |
506,455
+222,100
| +78% | +$19.4M | 0.13% | 166 |
|
|
2020
Q2 | $25.5M | Buy |
284,355
+95,800
| +51% | +$9.68M | 0.07% | 273 |
|
|
2020
Q1 | $18.8M | Buy |
188,555
+9,600
| +5% | +$1.04M | 0.07% | 304 |
|
|
2019
Q4 | $20.6M | Buy |
178,955
+39,400
| +28% | +$4.77M | 0.05% | 376 |
|
|
2019
Q3 | $17.6M | Sell |
139,555
-6,745
| -5% | -$856K | 0.04% | 399 |
|
|
2019
Q2 | $17.6M | Sell |
146,300
-28,255
| -16% | -$2.78M | 0.04% | 438 |
|
|
2019
Q1 | $15.3M | Buy |
174,555
+20,855
| +14% | +$1.9M | 0.04% | 481 |
|
|
2018
Q4 | $15.4M | Sell |
153,700
-8,205
| -5% | -$862K | 0.04% | 448 |
|
|
2018
Q3 | $18.6M | Sell |
161,905
-34,255
| -17% | -$3.55M | 0.05% | 410 |
|
|
2018
Q2 | $17.6M | Buy |
196,160
+42,060
| +27% | +$3.55M | 0.05% | 426 |
|
|
2018
Q1 | $11.3M | Sell |
154,100
-159,205
| -51% | -$10.9M | 0.03% | 539 |
|
|
2017
Q4 | $18.2M | Buy |
313,305
+219,300
| +233% | +$11.5M | 0.05% | 427 |
|
|
2017
Q3 | $4.22M | Buy |
94,005
+3,405
| +4% | +$141K | 0.01% | 867 |
|
|
2017
Q2 | $3.58M | Buy |
90,600
+8,200
| +10% | +$337K | 0.01% | 910 |
|
|
2017
Q1 | $3.34M | Buy |
82,400
+32,500
| +65% | +$1.27M | 0.01% | 996 |
|
|
2016
Q4 | $2.01M | Buy |
49,900
+35,595
| +249% | +$1.34M | 0.01% | 1177 |
|
|
2016
Q3 | $518K | Buy |
+14,305
| New | +$491K | ﹤0.01% | 1668 |
|
|
2016
Q2 | – | Sell |
-5,805
| Closed | -$203K | – | 2100 |
|
|
2016
Q1 | $203K | Buy |
+5,805
| New | +$187K | ﹤0.01% | 1824 |
|
|
2014
Q3 | – | Sell |
-124,005
| Closed | -$4.38M | – | 2462 |
|
|
2014
Q2 | $4.38M | Buy |
124,005
+23,800
| +24% | +$795K | 0.03% | 520 |
|
|
2014
Q1 | $3.27M | Buy |
+100,205
| New | +$3.83M | 0.03% | 572 |
|
Other funds holding HAE
RA
Two Sigma Advisers's HAE Position: Q4 2024 in Review
Two Sigma Advisers sold out of Haemonetics (HAE) in Q4 2024, closing a stake of 20,655 shares — an estimated $1.66M sold.
Two Sigma Advisers first reported a position in HAE in Q1 2014 and held it in 36 quarters. The position peaked at $44.2M in Q3 2020. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.
- Two Sigma Advisers reported no remaining Haemonetics position as of Q4 2024 after selling out during the quarter.
- Two Sigma Advisers sold 20,655 Haemonetics shares in Q4 2024, an estimated $1.66M.
- Two Sigma Advisers first reported a position in Haemonetics in Q1 2014 and held it in 36 quarters.
- Two Sigma Advisers's Haemonetics position peaked at $44.2M in Q3 2020.
- 309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.
Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.